1. AB0957 Is there a difference in the clinical presentation of juvenile systemic scleroderma patients according the age of onset: results from the juvenile scleroderma inception cohort www.juvenile-scleroderma.com. (15th June 2017) Authors: Foeldvari, I; Klotsche, J; Kasapçopur, O; Adrovic, A; Stanevicha, V; Terreri, MT; Alexeeva, E; Katsicas, M; Smith, V; Cimaz, R; Kostik, M; Lehman, T; Anton, J; Sifuentes-Giraldo, W-A; Sztajnbok, F; Avcin, T; Janarthanan, M; Santos, MJ; Moll, M; Nemcova, D Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 1389 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. THU0511 Tocilizumab is a promising treatment option for therapy resistent juvenile localised scleroderma patients. (15th June 2017) Authors: Foeldvari, I; Anton, J; Friswell, M; Bica, B; Inocencio, J de; Aquilani, A; Helmus, N Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 399 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗